Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer
about
Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related DiseasesCurrent perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary managementBiomarkers of Inflammation and Immune Function and Risk of Colorectal CancerNew insights into pancreatic cancer-induced paraneoplastic diabetesOxidative stress in prostate cancer patients: A systematic review of case control studiesThe relationship between RAGE gene four common polymorphisms and breast cancer risk in northeastern Han ChineseAssociation of insulin-related serum factors with colorectal polyp number and type in adult males.Piecewise exponential survival times and analysis of case-cohort data.Glycated hemoglobin and all-cause and cause-specific mortality in Singaporean Chinese without diagnosed diabetes: the Singapore Chinese Health Study.Serum glucose and fructosamine in relation to risk of cancerExpression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.Cross-sectional analysis of obesity and serum analytes in males identifies sRAGE as a novel biomarker inversely associated with diverticulosisOverexpression of the Receptor for Advanced Glycation Endproducts (RAGE) is associated with poor prognosis in gastric cancer.Dicarbonyl Induced Structural Perturbations Make Histone H1 Highly Immunogenic and Generate an Auto-Immune Response in CancerObesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality.Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma.Soluble receptor for advanced glycation end products and risk of liver cancer.Carbonyl stress in aging process: role of vitamins and phytochemicals as redox regulatorsEffect of RAGE gene polymorphisms and circulating sRAGE levels on susceptibility to gastric cancer: a case-control study.Glycative stress from advanced glycation end products (AGEs) and dicarbonyls: An emerging biological factor in cancer onset and progression.Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling.RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis.Serum B6 vitamers (pyridoxal 5'-phosphate, pyridoxal, and 4-pyridoxic acid) and pancreatic cancer risk: two nested case-control studies in Asian populations.Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis.Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.Clinical significance of immunogenic cell death biomarker rage and early growth response 1 in human primary gastric adenocarcinoma.Long-term physical activity leads to a significant increase in serum sRAGE levels: a sign of decreased AGE-mediated inflammation due to physical activity?A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women.
P2860
Q26747425-196B52A7-D085-40A6-B295-1C5311E05F26Q26781156-33384864-2DFA-41A5-B54D-05D3FC440A2CQ26796256-0AC062FF-B694-4F35-AB41-B242C7A67D7FQ27687766-D3CC6C06-D8A2-43A3-8EFC-AEBF8965E37DQ28068523-9E77FBB4-1F8C-4BB5-9FEE-F9C86735BA04Q33573207-1DD1E95F-9A93-41B1-9968-2450F3EDF8FAQ34135535-974D7842-A2F0-44BF-BA47-8EFDC29A5E5AQ34194857-8A62AF80-C56E-4C11-B024-163B6A78DAD2Q34545355-9256FFFB-ECB4-4A99-82C3-EF35C8BD7A4AQ34571468-7170E10B-FC73-47A9-90A7-59BD6AD3AB4FQ35140467-DF79D60D-CEB8-4AC8-8803-919A07209C23Q35150815-7EC6FAC2-8E01-459B-90DF-987F186846F2Q35364536-D55BA49B-4BEB-40A2-97D3-9907B7BAB786Q35759066-F088808D-1A24-4394-B3DC-0816FEF99F79Q35817986-090C5B82-FF10-4361-95E3-A5A4ACC5E0EEQ36429573-CD0B6055-F2FC-4DEF-B9A6-B9EFD8F69358Q36816945-88C404C3-0191-433E-B037-FAC08F8F4C78Q37225026-6CDB4699-0935-4DB5-97F5-67030B60B987Q37627994-882644B8-FF50-4E94-8004-9D2ECBEA0396Q38698770-7CF52DAF-4FCB-48F4-876B-D1A366092A36Q38948698-0E017E69-F075-4633-956E-FFA9B0E3BE93Q38982380-ED53A4A7-048D-49CD-B5E8-5442E3CF0A9BQ40481663-5E435630-E830-445C-89DD-2D38C266DE40Q43742322-623D8E31-BE01-45F8-8BA0-40CE24233547Q45796080-A8DF804E-7E99-429E-A16A-8F26E9BA9955Q46170208-6654AF95-E0B3-4AE6-9EC8-D11E5A49525AQ48170304-2BF21401-A008-463A-A021-D6D6CD54AE77Q52873877-84A13834-D76D-417B-A9EC-DEED310F27FB
P2860
Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Advanced glycation end product ...... and risk of colorectal cancer
@ast
Advanced glycation end product ...... and risk of colorectal cancer
@en
type
label
Advanced glycation end product ...... and risk of colorectal cancer
@ast
Advanced glycation end product ...... and risk of colorectal cancer
@en
prefLabel
Advanced glycation end product ...... and risk of colorectal cancer
@ast
Advanced glycation end product ...... and risk of colorectal cancer
@en
P2093
P2860
P50
P1476
Advanced glycation end product ...... and risk of colorectal cancer
@en
P2093
Barry I Graubard
Philip R Taylor
Stephanie J Weinstein
P2860
P304
P356
10.1158/1055-9965.EPI-11-0066
P577
2011-04-28T00:00:00Z